DNA Methylation and Vascular Function
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Illinois at Chicago
About this trial
The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive/therapeutic interventions such as aerobic exercise.
Eligibility criteria
Qualifiers
BMI ≥ 35 kg/m2
Between ages 18-50 years
Not pregnant
Approved for a bariatric surgery
Disqualifiers
To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded
Pregnant women will be excluded, as they will not be eligible for bariatric surgery
Current smokers
Currently abusing alcohol or drugs
Trial design
Treatments tested in this trial
- Exercise training
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Illinois at Chicago
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov